Shu Ling Hoshi
University of Tsukuba
18 Papers
114 Citations
Shu Ling Hoshi is an academic researcher from University of Tsukuba. The author has contributed to research in topics: Medicine & Cost effectiveness. The author has an hindex of 6, co-authored 8 publications.
Chat about Author
Papers
Economic evaluation of the 21-gene signature (Oncotype DX) in lymph node-negative/positive, hormone receptor-positive early-stage breast cancer based on Japanese validation study (JBCRG-TR03).
TL;DR: The inclusion of the 21-gene signature in Japan’s social health insurance benefit package for not only LN− diseases but also LN+ diseases is cost-effective and can be justifiable as an efficient use of finite resources for health care.
79
Cost-effectiveness of chronic kidney disease mass screening test in Japan.
Masahide Kondo,Kunihiro Yamagata,Shu Ling Hoshi,Chie Saito,Koichi Asahi,Toshiki Moriyama,Kazuhiko Tsuruya,Hideaki Yoshida,Kunitoshi Iseki,Tsuyoshi Watanabe +9 more
TL;DR: The results suggest that a population strategy for CKD detection such as mass screening using dipstick test and/or serum Cr assay can be justified as an efficient use of health care resources in a population with high prevalence of the disease such as in Japan and Asian countries.
Economic evaluation of 21-gene reverse transcriptase-polymerase chain reaction assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer in Japan
Masahide Kondo,Masahide Kondo,Shu Ling Hoshi,Hiroshi Ishiguro,Hiroshi Yoshibayashi,Masakazu Toi +5 more
TL;DR: The 21-gene reverse transcriptase-polymerase chain reaction assay with a patented algorithm is validated as a good predictor of prognosis and potential benefit from adjuvant chemotherapy for lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer, while its high cost raises concern about how to finance it.
54
Economic evaluation of the 70-gene prognosis-signature (MammaPrint®) in hormone receptor-positive, lymph node-negative, human epidermal growth factor receptor type 2-negative early stage breast cancer in Japan.
TL;DR: The introduction of the 70-gene prognosis-signature into Japanese practice of ER+, LN−, HER2− ESBC treatment by including it to Japan’s social health insurance benefit package has a reasonable chance to be judged as cost-effective and may be justified as an efficient deployment of finite health care resources.
26
Economic evaluation of intensive chemotherapy with prophylactic granulocyte colony-stimulating factor for patients with high-risk early breast cancer in Japan.
Hiroshi Ishiguro,Masahide Kondo,Shu Ling Hoshi,Masahiro Takada,Seigo Nakamura,Satoshi Teramukai,Kazuhiro Yanagihara,Masakazu Toi +7 more
TL;DR: Third-generation regimens with prophylactic G-CSF will yield improved outcomes at a greater cost, but estimated ICER values are still less than the suggested cost-effectiveness threshold value of yen6 million for a gain of 1 QALY.
18